Related Experiment Video
Updated: Jan 10, 2026

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
Real-World Experience with Eptacog Beta for On-Label and Off-Label Indications: The Spanish Experience
Jose Manuel Martin de Bustamante1, María Isabel Rivas-Pollmar1, Natalia Acedo2
1Department of Haematology, Hospital Universitario la Paz, 28046 Madrid, Spain.
Eptacog beta, a novel recombinant activated factor VII (rFVIIa), shows efficacy and safety for surgical prophylaxis and bleeding treatment in patients with hemophilia A with inhibitors. Its use is also promising in factor VII deficiency and acquired hemophilia cases.
Area of Science:
- Hematology
- Pharmacology
Background:
- Eptacog beta is a novel recombinant activated factor VII (rFVIIa) with a preclinical profile similar to eptacog alfa.
- Previous trials (PERSEPT 1 and 3) demonstrated its efficacy and safety for hemophilia A or B with inhibitors, leading to FDA and EMA approval.
- Recent real-world data support positive outcomes in this population.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioequivalence of Drugs: Drugs with Multiple Indications
Bioequivalence studies: Biowaivers
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

